| Literature DB >> 23907486 |
Anne Zajicek1, Michael J Fossler, Jeffrey S Barrett, Jeffrey H Worthington, Robert Ternik, Georgia Charkoftaki, Susan Lum, Jörg Breitkreutz, Mike Baltezor, Panos Macheras, Mansoor Khan, Shreeram Agharkar, David Douglas MacLaren.
Abstract
Despite the fact that a significant percentage of the population is unable to swallow tablets and capsules, these dosage forms continue to be the default standard. These oral formulations fail many patients, especially children, because of large tablet or capsule size, poor palatability, and lack of correct dosage strength. The clinical result is often lack of adherence and therapeutic failure. The American Association of Pharmaceutical Scientists formed a Pediatric Formulations Task Force, consisting of members with various areas of expertise including pediatrics, formulation development, clinical pharmacology, and regulatory science, in order to identify pediatric, manufacturing, and regulatory issues and areas of needed research and regulatory guidance. Dosage form and palatability standards for all pediatric ages, relative bioavailability requirements, and small batch manufacturing capabilities and creation of a viable economic model were identified as particular needs. This assessment is considered an important first step for a task force seeking creative approaches to providing more appropriate oral formulations for children.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23907486 PMCID: PMC3787237 DOI: 10.1208/s12248-013-9511-5
Source DB: PubMed Journal: AAPS J ISSN: 1550-7416 Impact factor: 4.009